Why Medicare Advantage isn’t as popular for first-year Medicare beneficiaries.
While enrollment in Medicare Advantage has grown rapidly over the past decade, the majority of Medicare beneficiaries choose to enroll in traditional Medicare during their first year on Medicare, according to the Kaiser Family Foundation (KFF).
A KFF Issue Brief found that older adults and younger beneficiaries with disabilities have said that they make this choice based on premiums and out-of-pocket costs, access to desired providers, the reputation of the company offering the plan, ads and other marketing materials, and the advice of brokers, family members, and friends.
Medicare Advantage offers one-stop shopping, with all Medicare benefits in one combined package, and enrollees may have lower out-of-pocket costs than those in traditional Medicare, with an out-of-pocket cap and coverage of some additional benefits, such as eyeglasses. Beneficiaries in traditional Medicare have open access to providers and fewer administrative hassles, such as prior authorization and referral requirements.
“We found that less than one-third (29%) of Medicare beneficiaries enrolled in Medicare Advantage plans during their first year on Medicare,” says Gretchen Jacobson, an associate director of the KFF’s Program on Medicare Policy. Most new beneficiaries (71%) were covered under traditional Medicare for their first year on Medicare.
“Enrollment rates among new Medicare beneficiaries were much higher in areas with high Medicare Advantage penetration rates and much lower in areas with low Medicare Advantage penetration rates,” Jacobson says. “In essence, new Medicare beneficiaries seem to be making care choices that are similar to other beneficiaries in their area.”
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More